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Atrial fibrillation (AF) is the most frequently encountered clinical arrhythmia and
is associated with increased morbidity and mortality. Ectopic activity and reentry
are considered major arrhythmogenic mechanisms contributing to the initiation and
maintenance of AF. In addition, AF is self-reinforcing through progressive electrical
and structural remodeling which stabilize the arrhythmia and make it more difficult
to treat. Recent research has suggested an important role for Ca2+-dysregulation in
AF. Ca2+-handling abnormalities may promote ectopic activity, conduction abnormalities
facilitating reentry, and AF-related remodeling. In this review article, we summarize the
Ca2+-handling derangements occurring in AF and discuss their impact on fundamental
arrhythmogenic mechanisms. We focus in particular on the role of the multifunctional
Ca2+/calmodulin-dependent protein kinase type-II (CaMKII), which acts as a major link
between Ca2+-dysregulation and arrhythmogenesis. CaMKII expression and activity are
increased in AF and promote arrhythmogenesis through phosphorylation of various targets
involved in cardiac electrophysiology and excitation-contraction coupling. We discuss
the implications for potential novel therapeutic strategies for AF based on CaMKII and
Ca2+-handling abnormalities.
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INTRODUCTION
Atrial fibrillation (AF) is the most prevalent heart-rhythm dis-
order, estimated to affect more than 33 million people world-
wide (Chugh et al., 2013). AF is associated with increased
morbidity and mortality, notably as a risk factor for stroke
and worsening of heart failure (Camm et al., 2012; Chugh
et al., 2013). Current pharmacological treatments for rhythm-
control of AF mainly include class-I and class-III antiarrhyth-
mic drugs, which have modest efficacy, providing sinus-rhythm
maintenance in only 30–70% of patients after >1 year of
follow-up (Camm, 2012). In addition, these drugs are asso-
ciated with substantial adverse side-effects including ventricu-
lar proarrhythmia and extra-cardiac toxicity (Zimetbaum, 2012;
Heijman et al., 2013a). The AF incidence is expected to increase
due to aging of the population, making the development of
improved antiarrhythmic treatments of critical importance. A
better understanding of AF pathophysiology is expected to
foster this development (Dobrev et al., 2012). Accumulating
evidence has highlighted a central role for abnormal Ca2+-
handling in AF-pathophysiology (Dobrev and Nattel, 2008;
Heijman et al., 2012; Nattel and Dobrev, 2012). Here, we
review recent studies detailing the proarrhythmic role of AF-
related Ca2+-handling abnormalities, with particular focus on
the contributions of the Ca2+/calmodulin-dependent protein
kinase type-II (CaMKII).
ATRIAL CELLULAR ELECTROPHYSIOLOGY AND
ARRHYTHMOGENIC MECHANISMS
NORMAL ATRIAL CELLULAR ELECTROPHYSIOLOGY AND
Ca2+-HANDLING
The atrial action potential (AP) is determined by depolariz-
ing and repolarizing ionic currents (Dobrev and Ravens, 2003).
Depolarizing currents include the cardiac voltage-gated Na+-
current (INa) and its persistent (“late”) component (INa,late), the
L-type Ca2+-current (ICa,L) and the Na+/Ca2+-exchanger type-1
(NCX1) current (INCX), which, in its forward mode, extrudes one
Ca2+-ion in exchange for 3 Na+-ions, resulting in a net depolar-
izing inward current. Repolarizing currents include the transient-
outward K+-current (Ito), delayed-rectifier K+-currents with
slow, rapid or ultra-rapid kinetics (IKs, IKr, and IKur, respectively),
as well as the Na+/K+-ATPase current (INaK). In addition, AP
duration (APD) and resting membrane potential are influenced
by basal and acetylcholine-activated inward-rectifier K+-currents
(IK1 and IK,ACh). The IKur and IK,ACh currents are predominantly
expressed in the atria, thereby providing potential atrial-specific
therapeutic targets.
Ca2+ entry through the L-type Ca2+-channel activates Ca2+-
induced Ca2+-release from the sarcoplasmic reticulum (SR)
through type-2 ryanodine receptor channels (RyR2), producing
the systolic Ca2+-transient responsible for initiating contrac-
tion of atrial cardiomyocytes (Bers, 2002). In addition, inositol
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1,4,5-triphosphate (IP3)-receptor-mediated Ca2+-release may
contribute to Ca2+-induced Ca2+-release by activating neighbor-
ing RyR2, although direct IP3-receptor-mediated activation of
NCX1 has also been described recently (Dobrev and Nattel, 2008;
Roderick and Knollmann, 2013).
Structural differences between atrial and ventricular
cardiomyocytes may further contribute to a unique atrial
Ca2+-handling profile. Isolated atrial cardiomyocytes generally
have a less well-developed T-tubular network than ventricular
cardiomyocytes. However, cardiomyocytes of certain species
including humans, sheep, goats, cows, and horses do have
more T-tubules than those from rodents (Dibb et al., 2009;
Lenaerts et al., 2009; Richards et al., 2011). At least in sheep, this
T-tubular system contributes to a more uniform, ventricular-like,
Ca2+-induced Ca2+-release (Dibb et al., 2009). Although a small
T-tubular system is present in human atrial myocytes, it shows
some variability depending on region and cardiomyocyte size
(Trafford et al., 2013). Moreover, this T-tubular system can be
remodeled by cardiac disease including AF (Lenaerts et al., 2009).
In atrial cardiomyocytes with a less well-developed T-tubular
structure, Ca2+-induced Ca2+-release starts at the plasma
membrane and propagates slowly toward the cell-center (Dobrev
et al., 2009; Bootman et al., 2011). Relaxation occurs when
Ca2+ is extruded from the cell via NCX1 and the plasmalemmal
Ca2+-ATPase (PMCA), or is taken back up into the SR by the
type-2a SR Ca2+-ATPase (SERCA2a). The affinity of SERCA2a
for intracellular Ca2+ is largely determined by the inhibitory
proteins phospholamban (PLB) and sarcolipin. The expression
of sarcolipin is atrial-specific, whereas PLB is more strongly
expressed in the ventricles than in the atria (Dobrev et al., 2009).
ARRHYTHMOGENIC MECHANISMS IN AF
AF can occur as a result of abnormalities in electrical impulse for-
mation or impulse conduction (Nattel et al., 2008; Wakili et al.,
2011; Heijman et al., 2014). Electrical impulse generation outside
of the sinoatrial node, termed ectopic activity, can sustain AF as
a driver, and can trigger reentry in a vulnerable substrate char-
acterized by a slow and inhomogeneous conduction and short
effective refractory periods. This vulnerable substrate can arise
from genetic conditions, normal aging, or co-morbidities such
as heart failure or hypertension (Wakili et al., 2011). Reentry
can occur around anatomical obstacles or can be functional (i.e.,
occurring in the absence of anatomical obstacles). Reentry is con-
sidered the predominant mechanism for AF maintenance. When
AF is maintained, atrial tachycardia-related remodeling produces
electrical and structural alterations that further promote AF
maintenance and stabilization, contributing to the progression
toward longer-lasting AF episodes that are more difficult to treat.
At the cellular level, the effective refractory period is
determined by APD and post-repolarization refractoriness.
Conduction velocity is influenced by the depolarizing force
through INa, and the electrical conduction between atrial car-
diomyocytes is controlled by gap-junction channels as well as
the structure of the atrial myocardium, notably the amount
and composition of the extracellular matrix, particularly fibrosis.
The cellular mechanisms of ectopic activity mainly involve early
and delayed afterdepolarizations (EADs and DADs, respectively).
EADs are caused primarily by recovery from inactivation of ICa,L
during excessive APD-prolongation, for example due to loss of
repolarizing K+-currents. DADs are likely the most common
mechanism underlying ectopic (triggered) activity and result
from intracellular Ca2+-handling abnormalities. Spontaneous
diastolic SR Ca2+-release events resulting from SR Ca2+-overload
or intrinsic RyR2-dysfunction can activate NCX1, resulting in a
transient-inward current that depolarizes the membrane poten-
tial as Ca2+ is extruded from the atrial cardiomyocyte (Dobrev
andWehrens, 2010). When the threshold for excitation is reached
in a sufficient number of cardiomyocytes, an ectopic impulse is
generated (Wakili et al., 2011).
STRUCTURE, ACTIVATION AND TARGETS OF CaMKII
CaMKII is a multifunctional serine/threonine protein kinase that
is abundantly expressed in various tissues including the heart
(Swaminathan et al., 2012). There are four CaMKII isoforms,
with CaMKIIδ being the most abundant in heart. CaMKIIδ
has a hypervariable region, giving rise to multiple splice vari-
ants, including a splice variant with a nuclear localization sig-
nal (NLS; CaMKIIδB) and one without such NLS sequence
(CaMKIIδC). The latter was traditionally considered cytosolic
(Swaminathan et al., 2012), although this localization is not abso-
lute (Mishra et al., 2011). CaMKII is a holoenzyme consisting
of two stacked hexameric rings of subunits. Each subunit has
a catalytic domain that, under resting conditions, is inhibited
by regulatory domains of neighboring subunits. When intra-
cellular Ca2+-levels periodically rise during the cellular Ca2+-
transient, Ca2+ binds to calmodulin and activates CaMKII by
binding to the regulatory domain (Swaminathan et al., 2012).
CaMKII subunits can auto-phosphorylate Thr287 on neighbor-
ing subunits, thereby hindering the re-association of the catalytic
and regulatory domains, producing sustained Ca2+-independent
activation. This mechanism makes CaMKII activation strongly
heart rate-dependent, with accumulating activity at faster rates.
Furthermore, CaMKII can show Ca2+-independent activation
following oxidation of Met281/282 by reactive oxygen species
(Erickson et al., 2008), via O-linked glycosylation of Ser280 by
O-linked N-acetylglucosamine (Erickson et al., 2013), and via
NO-dependent nitrosylation of Cys116, Cys273, or Cys290, the
exact residue being at present unknown (Gutierrez et al., 2013). In
contrast, phosphorylation of Thr306/307 promotes CaMKII inac-
tivation by reducing the binding of Ca2+/calmodulin complexes
(Colbran, 1993).
CaMKII can phosphorylate multiple substrates in atrial car-
diomyocytes (Figure 1). CaMKII-dependent phosphorylation of
L-type Ca2+-channels produces high-activity mode-2 gating
resulting in increased open probability of ICa,L, thereby aug-
menting the amount of Ca2+ entering the atrial cardiomyocyte.
CaMKII also contributes to the increase in ICa,L following
repeated depolarizing pulses (termed Ca2+-dependent ICa,L-
facilitation) (Swaminathan et al., 2012). CaMKII-dependent
phosphorylation of Nav1.5 slows INa inactivation and augments
the non-inactivating, “late” component of INa (Wagner et al.,
2011). The Kv4.3 pore-forming subunit of Ito is also regulated
by CaMKII-dependent phosphorylation through the accessory
protein SAP97, resulting in increased Ito that would tend to
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shorten APD (El-Haou et al., 2009; Wagner et al., 2009). Based
on experiments involving CaMKII inhibition with an inhibitory
peptide or the experimental drug KN-93, CaMKII also appears
to acutely augment IK1 (Wagner et al., 2009) and IKur (Tessier
et al., 1999), thereby offsetting the APD-prolonging effects of
CaMKII-dependent ICa,L and INa phosphorylation. In addition,
both PLB and sarcolipin can undergo CaMKII-dependent phos-
phorylation, causing disinhibition of SERCA2a and increasing SR
Ca2+-reuptake (Dobrev and Wehrens, 2010). Finally, CaMKII-
dependent hyperphosphorylation of Ser2814 on RyR2 increases
channel open probability, augmenting SR Ca2+-release. Taken
together, CaMKII plays a nodal role in the modulation of atrial
cellular Ca2+-handling.
Ca2+/ CaMKII DYSREGULATION IN AF
MECHANISMS PROMOTING CaMKII DYSREGULATION IN AF
CaMKIIδ protein expression and activity are increased in dogs
with pacing-induced atrial tachycardia remodeling (Wakili et al.,
2010), goats with long-standing AF (Greiser et al., 2009), and
patients with chronic AF (cAF); (Tessier et al., 1999; Neef et al.,
2010; Voigt et al., 2012), suggesting that increased CaMKII func-
tion can be a consequence of AF. Activation of CaMKII appears
to be regulated locally within the myocyte, since autophos-
phorylation of Thr287 was increased for CaMKIIδC but not
CaMKIIδB in patients with cAF (Voigt et al., 2012). Several AF-
related conditions, including sympathetic hyperactivity, oxida-
tive stress and atrial tachycardia per se, may promote CaMKII
activation (Figure 2). High atrial-rates during AF can acti-
vate CaMKII via frequency-dependent mechanisms. In addition,
neuronal autonomic dysbalance can contribute to AF initia-
tion (Park et al., 2012) and atrial tachycardia, in turn, pro-
motes neural remodeling including heterogeneous sympathetic
hyperactivity (Jayachandran et al., 2000). Increased sympa-
thetic activity can activate CaMKII through various pathways,
including protein kinase-A (PKA)-dependent augmentation of
cellular Ca2+-cycling (Grimm and Brown, 2010). In addi-
tion, PKA-independent, exchange-protein activated by cAMP
(Epac) can activate CaMKII following β-adrenoceptor stimula-
tion (Mangmool et al., 2010; Pereira et al., 2013). Moreover,
β1-adrenoceptor-activated Epac2 can promote SR Ca2+-leak via
phosphorylation of RyR2-Ser2814 (Pereira et al., 2013). It has
also been suggested that the Epac-mediated CaMKII activation
involves phosphorylation of CaMKII-Thr287 by protein kinase-
C type-ε (PKCε) (Oestreich et al., 2009) and the upregulation
of PKCε in cAF patients (Voigt et al., 2008) might contribute
to increased CaMKII activity. Since PKCε translocation to the
membrane is increased in atrial myocytes following in vitro
tachypacing (Makary et al., 2011), this might promote local
atrial tachycardia-dependent CaMKII stimulation, although this
remains to be proven in future studies. AF is also associated
with oxidative stress and oxidation of CaMKII is increased in AF
patients (Purohit et al., 2013). Conversely, phosphorylation of the
inhibitory Thr306/307 site is decreased in cAF patients, providing
another pathway of CaMKII activation in AF (Voigt et al., 2012).
Atrial CaMKII activity is also increased in dogs with ventric-
ular tachypacing-induced heart failure (Yeh et al., 2008), and in
goats with atrial dilatation (Greiser et al., 2009), suggesting that
CaMKII can be activated by AF-enabling cardiac pathologies,
potentially contributing to the evolution of a vulnerable sub-
strate for AF initiation. Similarly, increased body-mass index and
diabetes are AF risk-factors (Dublin et al., 2006) that may fur-
ther promote CaMKII activation via O-linked glycosylation in
response to hyperglycaemia (Erickson et al., 2013). Thus, CaMKII
activation is multifactorial, resulting from AF itself, as well as
from AF-enabling risk factors and diseases (Figure 2).
ROLE OF CaMKII IN ECTOPIC ACTIVITY
CaMKII has been shown to promote EADs in ventricular car-
diomyocytes (Qi et al., 2009), which can produce ectopic (trig-
gered) activity. CaMKII-dependent phosphorylation of ICa,L
slows ICa,L inactivation, increasing the ICa,L window current that
plays a major role in the generation of EADs (Qi et al., 2009).
In addition, the APD-prolonging effects of CaMKII-dependent
phosphorylation of INa, increasing INa,late, could further pro-
mote the occurrence of EADs and ectopic activity (Wagner et al.,
2011). However, since most forms of AF are generally associ-
ated with abbreviated APD, the relevance of such EADs may be
lower in atrial compared to ventricular arrhythmogenesis. On the
other hand, EADs can also arise from Ca2+-handling abnormali-
ties that activate depolarizing NCX-current (late phase-3 EADs),
which have been implicated in the initiation of AF in some ani-
mal models (Burashnikov and Antzelevitch, 2003; Patterson et al.,
2006).
Ca2+-handling abnormalities can also cause DADs and ectopic
(triggered) activity, promoting AF initiation. Genetic mouse
models have revealed that intrinsic RyR2-dysfunction is suf-
ficient to increase the susceptibility to pacing-induced AF, as
reviewed in (Dobrev et al., 2011). Mice with gain-of-function
RyR2 mutations causing catecholaminergic polymorphic ventric-
ular tachycardia (CPVT), and mice lacking the RyR2-stabilizing
subunit FKBP12.6, develop Ca2+-handling abnormalities includ-
ing increased SR Ca2+-leak and spontaneous SR Ca2+-release
events (i.e., sparks, waves). These mice also have an increased
susceptibility to pacing-induced AF (Sood et al., 2008; Chelu
et al., 2009; Shan et al., 2012). Rapid-pacing activates CaMKII and
increases CaMKII-dependent RyR2 and PLB phosphorylation.
Genetic and pharmacological CaMKII inhibition normalized the
susceptibility to pacing-induced AF in mice with a CPVT muta-
tion in RyR2 (Chelu et al., 2009). Of note, selective genetic
inhibition of CaMKII-dependent RyR2-hyperphosphorylation
(RyR2-Ser2814Ala) also reduced the incidence of rapid-pacing-
induced AF in mice where a vulnerable substrate was created
using stimulation with the muscarinic-receptor agonist carba-
chol, and pacing-induced AF in mice deficient of FKBP12.6
(Chelu et al., 2009; Li et al., 2012), strongly suggesting that
CaMKII-dependent RyR2 hyperphosphorylation and associated
Ca2+-handling abnormalities are critical AF-promoting factors
(Dobrev et al., 2011). In addition, recent work has identified
calmodulin as a direct regulator of RyR2 that stabilizes SR Ca2+-
release (Yang et al., 2014). Although overall calmodulin levels
are increased in cAF patients (Voigt et al., 2012), a reduced
affinity between RyR2 and calmodulin, as observed in heart fail-
ure (Yang et al., 2014), could potentially contribute to RyR2
dysfunction in AF.
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FIGURE 1 | Putative substrates for CaMKII-dependent phosphorylation
in atrial cardiomyocytes and their consequences for atrial cellular
electrophysiology and Ca2+-handling. CaMKII can phosphorylate the
transient-outward K+-current (Ito), inward-rectifier K+-current (IK1) and
ultra-rapid delayed-rectifier K+-current (IKur), augmenting their functions and
shortening action potential duration (APD). Phosphorylation of L-type
Ca2+-current (ICa,L) and Na+-current (INa; resulting in an increased late
component: INa,late) by CaMKII increases intracellular Ca2+ levels and
prolongs APD. CaMKII-dependent phosphorylation of phospholamban (PLB)
and sarcolipin (SLN) increases sarcoplasmic reticulum (SR) Ca2+-uptake,
whereas phosphorylation of type-2 ryanodine-receptor channels (RyR2)
promotes diastolic SR Ca2+-leak. CaMKII-dependent increases in expression
of Na+/Ca2+-exchanger type-1 (NCX1) augment NCX-current (INCX),
promoting the occurrence of delayed afterdepolarizations (DADs). In addition,
Ca2+-handling abnormalities can activate small-conductance Ca2+-activated
K+-currents (ISK) and agonist-independent “constitutive” IK,ACh, shortening
APD, and promote altered gene expression via the Ca2+-dependent
phosphatase calcineurin (Cn).
Atrial cardiomyocytes from cAF patients have unaltered
RyR2 protein expression levels and SR Ca2+-load (Voigt
et al., 2012). However, they exhibit CaMKII-dependent RyR2-
hyperphosphorylation that increases RyR2 open probability and
augments SR Ca2+-leak and spontaneous diastolic Ca2+-release
events. The enhanced SR Ca2+ leak results in enhanced DADs
and cellular triggered activity and can be blocked using CaMKII
inhibitors, thus supporting an important proarrhythmic role
for these CaMKII-dependent Ca2+-handling abnormalities in
human AF (Voigt et al., 2012). In addition, cAF patients
had significantly reduced levels of RyR2-stabilizing FKBP12.6
subunits (Vest et al., 2005) and larger transient-inward cur-
rents/depolarizations for a given SR Ca2+-release. The latter is in
part mediated by increased NCX1 mRNA (Gaborit et al., 2005)
and protein expression levels (Schotten et al., 2002; El-Armouche
et al., 2006; Voigt et al., 2012) in cAF patients. There is evi-
dence that CaMKII can upregulate NCX1 transcription following
β-adrenoceptor stimulation (Mani et al., 2010), suggesting that
CaMKII could also be involved in the increased NCX1 expres-
sion in AF. Although atrial cardiomyocytes from paroxysmal
AF (pAF) patients also have increased SR Ca2+-leak, sponta-
neous SR Ca2+-release events and DADs, these effects appear to
be CaMKII-independent, since CaMKII expression and Thr287
autophosphorylation were not changed in pAF patients (Voigt
et al., 2014). Similarly, CaMKII-dependent PLB and RyR2 phos-
phorylation, as well as NCX1 expression were also unaltered in
pAF patients. However, RyR2 expression and RyR2 single-channel
open-probability were increased and SR Ca2+-load was larger
in pAF, likely due to PKA-dependent PLB hyperphosphorylation
(Voigt et al., 2014). Computational modeling showed that both
increased SR Ca2+-load and RyR2 dysregulation contribute to the
spontaneous diastolic SR Ca2+-release events in cardiomyocytes
from pAF patients. Thus, although SR Ca2+-handling abnormal-
ities appear a central element in experimental and human AF, the
underlying molecular mechanisms are complex. In addition, it
is likely that the proarrhythmic consequences of Ca2+-handling
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FIGURE 2 | Atrial fibrillation (AF)-related mechanisms promoting
CaMKII activation. AF-promoting conditions and/or AF itself can activate
CaMKII via high atrial rates, oxidative stress, sympathetic hyperactivity, and
hyperglycaemia, resulting in post-translational modifications
(phosphorylation, oxidation, nitrosylation and glycosylation) of various
residues in the regulatory domain of CaMKII. In addition, AF is associated
with an increased total expression of the CaMKII holoenzyme. See text for
details.
abnormalities are distinct for different types of AF (Figure 3).
Whereas Ca2+-mediated triggered activity is a likely candidate for
the re-initiation of AF episodes in pAF patients, its relevance for
patients with long-standing persistent AF is incompletely under-
stood. In persistent AF forms, Ca2+-dependent evolution and
progression of atrial remodeling may play a prominent role in
arrhythmia maintenance and stabilization (as discussed below).
ROLE OF CaMKII IN REENTRY-PROMOTING REMODELING
Ca2+-handling abnormalities also play a role in AF-promoting
reentry. APD-shortening is a hallmark feature of AF-related
remodeling that facilitates the maintenance of reentrant circuits.
It is largely mediated by a reduction in depolarizing ICa,L and
an increase in several repolarizing K+-currents. Various mech-
anisms contribute to reduced ICa,L in AF (Dobrev et al., 2012).
Cav1.2 expression is reduced in AF through a pathway involving
the Ca2+-dependent phosphatase calcineurin and nuclear fac-
tor of activated T-cells (NFAT) (Qi et al., 2008) and increased
activation of the Ca2+-dependent protease calpain promotes
breakdown of ICa,L channels (Brundel et al., 2004). ICa,L phos-
phorylation is also reduced in AF, decreasing current ampli-
tude, and could be due to either increased protein phosphatase
activity or local reduction in CaMKII availability (Christ et al.,
2004). IK1 is increased in cAF patients, and, together with an
increase in the acetylcholine-independent “constitutive” activity
of IK,ACh, results in an overall increase in inward-rectifier K+-
current that contributes to APD shortening (Dobrev et al., 2005).
A Ca2+-dependent NFAT-mediated reduction in the inhibitory
microRNA-26 in AF results in disinhibition of Kir2.1 expres-
sion, contributing to the increase in IK1 in cAF patients (Luo
et al., 2013). Increased constitutive IK,ACh may also result from
Ca2+-dependent calpain-mediated reduction in inhibitory PKCα
(Makary et al., 2011). Thus, the proarrhythmic increases in IK1
and constitutive IK,ACh are partially mediated by Ca2+-dependent
processes, althouth the potential involvement of CaMKII needs
to be specifically addressed in future studies. Finally, the Ca2+-
dependent small-conductance (SK) K+-current (ISK) is upregu-
lated in atria of cAF patients, which might contribute to APD
shortening (Zhou et al., 2012), although others have reported
reduced ISK in AF (Yu et al., 2012). Acute Ca2+-dependent reg-
ulation of currents such as INa, ISK or ICa,L can also contribute
to beat-by-beat alterations in APD, including APD alternans and
augmentation of dispersion of repolarization. These spatial and
temporal repolarization heterogeneities favor unidirectional con-
duction block that can initiate reentry. In agreement, atrial APD
alternans is emerging as a clinical index to assess the vulnerability
to develop AF in patients (Lalani et al., 2013).
Ca2+-entry into atrial fibroblasts via multiple ion chan-
nels contributes to fibroblast proliferation and differentiation
into collagen-secreting myofibroblasts, which promote fibrosis-
induced heterogeneous conduction slowing and reentry (Yue
et al., 2011). Transient-receptor potential (TRP) melastatin-
related-7 (TRPM7) and canonical-3 (TRPC3) channels are major
sources of Ca2+-entry into human atrial fibroblasts (Du et al.,
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FIGURE 3 | Proarrhythmic consequences of Ca2+/CaMKII dysregulation
in atrial fibrillation (AF). CaMKII activation and CaMKII-dependent
phosphorylation of type-2 ryanodine-receptor (RyR2) channels
(RyR2-Ser2814-P) and phospholamban (PLB-Thr17-P), as well as other
factors, promote spontaneous diastolic sarcoplasmic reticulum (SR)
Ca2+-release events through RyR2 dysfunction and modulation of SR
Ca2+-load in patients with paroxysmal AF (pAF; blue lines) and
long-standing persistent, chronic AF (cAF; black lines). SR Ca2+-leak and
diastolic SR Ca2+-release events can produce delayed afterdepolarizations
(DADs) that contribute to ectopic activity. In addition, they can promote
reentry through local repolarization abnormalities, as well as structural
remodeling and conduction velocity (CV) slowing. Influences for which
the proarrhythmic roles are more speculative have been indicated with
dashed lines.
2010; Harada et al., 2012). Atrial fibroblasts from AF-patients
have larger TRPM7 currents and increased TRPC3 expres-
sion, and are more prone to differentiate into myofibroblasts.
Knockdown of TRPM7 expression reduces basal differentiation
of fibroblasts from cAF patients (Du et al., 2010). Furthermore,
pharmacological inhibition of TRPC3 channels reduces AF sub-
strate development and AF duration in dogs with electrically
maintained AF (Harada et al., 2012). TRPM7-like channels are
inhibited by CaMKII in hepatocytes, which may support hep-
atocellular survival during proliferation (Mishra et al., 2009).
Moreover, Ca2+-influx through TRPC3 promotes CaMKII activa-
tion and NADPH-oxidase-mediated production of reactive oxy-
gen species in a genetic mousemodel (Kitajima et al., 2011). Thus,
CaMKII could potentially act both upstream and downstream
of TRP channels to alter fibroblast function in AF, although this
requires confirmation in subsequent studies.
Ca2+-handling abnormalities can also promote reentry by
reducing atrial conduction velocity through a reduction in INa
or direct inhibition of gap-junction channels in atrial cardiomy-
ocytes (Heijman et al., 2013b; King et al., 2013b). The reduction
in conduction velocity observed in mice with RyR2 mutations
could be reproduced in wild-type mice with acute applica-
tion of caffeine to increase SR Ca2+-leak, and appears to be
due to both acute Ca2+-dependent inhibition of INa, as well
as downregulation of Nav1.5 subunit expression under chronic
conditions (King et al., 2013a). This Ca2+-dependent reduc-
tion in INa is expected to promote reentry-mediated AF main-
tenance but may also reduce the likelihood of ectopic activ-
ity (Heijman et al., 2013b). At present the role of CaMKII
in these reentry-promoting Ca2+-handling abnormalities is
largely unknown, although it has been suggested that CaMKII-
dependent phosphorylation could also reduce peak INa, partic-
ularly at fast heart rates relevant for AF (Wagner et al., 2006),
which could contribute to reentry by reducing atrial conduction
velocity.
Cardiac myosin-binding protein-C (cMyBPC) is a critical
regulator of myofilament function (Schlossarek et al., 2011).
Ser282-phosphorylation of cMyBPC is decreased in dogs with
pacing-induced atrial tachycardia remodeling (Wakili et al.,
2010), in dogs with ventricular tachypacing-induced heart fail-
ure (Yeh et al., 2008), goats with long-standing AF or atrial
dilatation (Greiser et al., 2009), and in cAF patients (Tessier
et al., 1999; Neef et al., 2010; Voigt et al., 2012). Although
there is indirect evidence that this could be due to increased
local dephosphorylation by phosphatases, reduced local CaMKII-
dependent phosphorylation of Ser282 could also be involved. In
addition, contractile dysfunction is promoted by activation of
Ca2+-dependent proteases. Together, contractile dysfunction and
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associated atrial dilatation result in a larger vulnerable substrate,
promoting reentrant arrhythmias (De Jong et al., 2011).
Accumulating evidence suggests that CaMKII-dependent
RyR2-hyperphosphorylation and the related SR Ca2+-leak play
an important role in AF-promoting structural remodeling. Mice
with transgenic overexpression of the transcriptional repres-
sor CREM-IbC-X in cardiomyocytes (CREM mice) develop
age-dependent progression from spontaneous atrial ectopy to
paroxysmal and long-lasting AF episodes (Li et al., 2014).
The development of spontaneous AF episodes is preceded by
Ca2+-handling abnormalities and atrial enlargement. Genetic
inhibition of CaMKII-dependent RyR2 phosphorylation (RyR2-
Ser2814Ala) in CREM mice prevents Ca2+-handling abnormal-
ities and spontaneous AF, as well as atrial dilatation and con-
duction abnormalities (Li et al., 2014). Thus, CaMKII-dependent
RyR2-dysregulation not only contributes to ectopic (triggered)
activity, but also drives a progressive development of an AF sub-
strate (Figure 3), promoting atrial hypertrophy and dilatation,
and AF progression (Li et al., 2014). These studies suggest the
interesting possibility that the progression of AF might be inhib-
ited by targeted treatment of CaMKII or SR Ca2+-leak via RyR2.
Future studies in mice and large animal models are required to
confirm this concept, since the pathophysiological mechanisms
and the importance of CaMKII likely vary for different species
and experimental AF models, as well as for different forms of
clinical AF.
CaMKII DYSREGULATION AND Ca2+-HANDLING
ABNORMALITIES AS THERAPEUTIC TARGETS IN AF
The central role of Ca2+-handling abnormalities in AF-
pathophysiology suggests their potential as antiarrhythmic
targets. Stabilization of RyR2 has emerged as a viable
approach to normalize Ca2+-handling abnormalities. Several
currently-available antiarrhythmic drugs, including the class-Ic
Na+-channel blocker flecainide (Hilliard et al., 2010), the
β-adrenoceptor blocker carvedilol (Zhou et al., 2011), and
the antianginal drug ranolazine (Parikh et al., 2012), directly
bind and inhibit RyR2 channels. Indeed, flecainide has been
successfully employed in other Ca2+-dependent arrhythmias
such as CPVT (Van Der Werf et al., 2011). However, flecainide
also inhibits atrial K+-currents like IK,ACh (Voigt et al., 2010),
which might contribute to its anti-AF efficacy. More specific
RyR2 inhibitors are currently being evaluated in clinical studies
(Dobrev et al., 2012).
Inhibition of CaMKII or elimination of CaMKII-dependent
RyR2-phosphorylation has proven antiarrhythmic in mouse
models of AF and has shown beneficial effects in atrial cardiomy-
ocytes from cAF patients (Chelu et al., 2009; Li et al., 2012; Voigt
et al., 2012). However, given the importance of CaMKII in var-
ious physiological processes, systemic CaMKII inhibition could
have various undesirable side effects, including reduced fertil-
ity and impaired memory (Backs et al., 2010; Halt et al., 2012).
Moreover, since CaMKII expression/autophosphorylation and
CaMKII-dependent phosphorylation of RyR2 and PLB are not
increased in pAF patients (Voigt et al., 2014), it is unclear whether
CaMKII inhibition would be beneficial for this group of patients.
Nonetheless, it appears likely that localized CaMKII inhibition
could be a promising antiarrhythmic strategy for appropriately-
selected AF patients. Future animal studies and clinical trials
will be needed to determine which groups of AF patients are
most likely to benefit from CaMKII inhibition. Local inhibi-
tion of CaMKII might be possible through inhibition of specific
CaMKII-isoforms and splice variants, or by modulating differ-
ent CaMKII-targeting proteins. Another potential avenue could
be the modulation of microRNAs. Injection of complementary
“antagomirs” to reduce the activity of certain microRNAs or
overexpression of microRNAs has proven beneficial in a vari-
ety of experimental models, as reviewed in (Kumarswamy and
Thum, 2013). Recent work has shown that CaMKIIδ expression
is repressed by microRNA-145 (Cha et al., 2013) and microRNA-
30b-5p (He et al., 2013). Increasing the levels of these microRNAs
in the heart might, therefore, be an option to inhibit CaMKII.
CONCLUSIONS
Ca2+-handling abnormalities promote both focal ectopic (trig-
gered) activity and reentry that contribute to AF initiation and
maintenance. The expected increase in the incidence of AF and
the limited efficacy and safety of currently available antiarrhyth-
mic drugs, make a better understanding of these AF-modulating
processes critical for the development of improved therapeutic
strategies. Ca2+-handling abnormalities provide a novel set of
potential antiarrhythmic targets for the treatment of AF. However,
due to the multitude of etiologies and complexity of mecha-
nisms underlying clinical AF, it is likely that tailored therapeutic
strategies for specific groups of patients that target multiple
pathophysiological processes will be necessary. Cardiac-specific
inhibition of CaMKII could be a promising therapeutic strategy
for certain groups of AF patients.
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